NCT07244367 Maintenance Venetoclax in AML Fit Patients
| NCT ID | NCT07244367 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sohag University |
| Condition | Acute Myeloid Leukaemia (AML) |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2025-09-01 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
this study will explore the efficacy of maintenance SC cytarabine + venetoclax therapy as regard disease free survival (DFS) in AML fit patients who achieved CR after highly aggressive chemotherapy as bridge for BMT or if BMT will be delayed or canceled due to any other reason.
Eligibility Criteria
Inclusion Criteria: * Age : 18 - 60 years . Patients who are not eligible for immediate bone marrow transplantation. Newly diagnosed AML patients who attained CR after 1st line. Refractory / recurrant AML patients who attained CR after 2nd line . Exclusion Criteria: * Patients not on CR . Age : younger than 18 or older than 60 . Patients not eligible for bone marrow transplation
Contact & Investigator
Elsayed M Ali, Professor
STUDY DIRECTOR
Faculty of medicine sohag university
Frequently Asked Questions
Who can join the NCT07244367 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Acute Myeloid Leukaemia (AML). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07244367 currently recruiting?
Yes, NCT07244367 is actively recruiting participants. Contact the research team at Eman011065@med.sohag.edu.eg for enrollment information.
Where is the NCT07244367 trial being conducted?
This trial is being conducted at Sohag, Egypt, Sohag, Egypt.
Who is sponsoring the NCT07244367 clinical trial?
NCT07244367 is sponsored by Sohag University. The principal investigator is Elsayed M Ali, Professor at Faculty of medicine sohag university. The trial plans to enroll 80 participants.